Patent ID: 11884715
Assignee: KEROS THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  Y | IPC A  C

Claim 0:
1. A polypeptide comprising an extracellular activin receptor type IIB (ActRIIB) variant, the variant having one or more amino acid substitutions relative to the sequence of GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKG CWLDDFNCYDRQE CVATEENPQVYFCCCEGNFCNERFTHLPEAGGPEVTYEPPPTA PT (SEQ ID NO: 17),
wherein the variant comprises one or more amino acid substitutions that impart reduced binding to bone morphogenetic protein 9 (BMP9) relative to wild type extracellular ActRIIB;
wherein the variant comprises:
(i) amino acid substitutions Q69T, E70D, I11L, L27V, Q34K, T50S, I51L, L53I, and F89M;
(ii) amino acid substitutions Q69T, E70D, E75K, I11L, L27V, Q34K, T50S, I51 L, L53I, and F89M;
(iii) amino acid substitutions Q69D, E70T, I11L, L27V, Q34K, T50S, I51L, L53I, and F89M; or
(iv) amino acid substitutions Q69D, E70T, E75K, I11L, L27V, Q34K, T50S, I51 L, L53I, and F89M; and
wherein the variant has at least 85% amino acid sequence identity to the sequence of SEQ ID NO: 17.